作者: Wilson-Shabazz, Imani ; Singley, Katie ; Luck, Caseem ; Murali, Swathi ; Cabey, Whitney ; Verma, Shreya ; Rotaru, Alexandru-Mircea ; Kerstetter, Molly ; Bauerle Bass, Sarah ; Gardiner, Heather ; Paulus, Kirsten ; Knight, Elizabeth ; Hoadley, Ariel

BACKGROUNDUnderlying causes of vaccine hesitancy could significantly affect successful uptake of the SARS-CoV2 vaccine booster doses during new waves of COVID-19. Booster rates among US adults are far below what is needed for immunity, but little is known about booster hesitancy among fully vaccinated adults and whether medical mistrust exacerbates barriers to uptake.METHODSA cross-sectional survey was completed among 119 adults in Philadelphia, PA who reported having received the primary SARS-CoV2 vaccine series but not a booster dose. Using the LaVeist Medical Mistrust (MM) Index, a k-means cluster analysis showed two clusters (Low MM, High MM) and differences in attitudes and perceptions about COVID-19 booster vaccines were assessed using F-tests.RESULTSRespondents were 62% Black and female; mean age was 41; 46% reported earning less than $25,000 and 53% had a high school education or less. Overall intention to get boosted was low (mean 3.3 on 0-10 scale). Differences in COVID-19 booster perceptions between those with High (n = 56) vs. Low (n = 59) MM were found, independent of any demographic differences. Most statements (7/10) related to reasons to not be boosted were significant, with those with High MM indicating more concern about feeling sick from the vaccine (F=-3.91, p≤ .001), beliefs that boosters are ineffective for vaccinated people (F= -3.46, p≤ .001), and long-term side effect worries (F=-4.34, p≤ .001). Those with High MM were also more concerned about the adverse effects of the vaccine (F=-2.48, p=.02), but were more likely to trust getting information from doctors or healthcare providers (F= -2.25, p=.03).CONCLUSIONSResults indicate that medical mistrust is an important independent construct when understanding current COVID-19 booster hesitancy. While much work has looked at demographic differences to explain vaccine hesitancy, these results suggest that further research into understanding and addressing medical mistrust could be important for implementing interventions to increase booster rates.

2024-09-01·iScience

Low booster uptake in cancer patients despite health benefits

Article

作者: Nadri, Maimoona ; Ramanujan, V. Krishnan ; Choi, So Yung ; Gong, Jun ; Darrah, Justin M ; Hendifar, Andrew E ; Hamid, Omid ; Merin, Noah M ; Tourtellotte, Warren G. ; Tourtellotte, Warren G ; Mita, Alain C. ; Merchant, Akil A. ; Mahov, Simeon ; Huynh, Carissa A. ; Figueiredo, Jane C. ; Ramanujan, V Krishnan ; Xu, Alexander M. ; Merin, Noah M. ; Nguyen, Nathalie ; Figueiredo, Jane C ; Vescio, Robert A ; Paquette, Ronald L ; Gonzalez, Alma ; Reckamp, Karen L ; Salvy, Sarah J. ; Lemos, Tucker ; Reckamp, Karen L. ; Natale, Ronald ; Merchant, Akil A ; Darrah, Justin M. ; Hendifar, Andrew E. ; Salvy, Sarah J ; Mita, Alain C ; Levy, Julia ; Xu, Alexander M ; Vescio, Robert A. ; Sobhani, Kimia ; Paquette, Ronald L. ; Mehmi, Inderjit ; Huynh, Carissa A

Patients with cancer are at increased risk of death from COVID-19 and have reduced immune responses to SARS-CoV2 vaccines, necessitating regular boosters. We performed comprehensive chart reviews, surveys of patients attitudes, serology for SARS-CoV-2 antibodies and T cell receptor (TCR) β sequencing for cellular responses on a cohort of 982 cancer patients receiving active cancer therapy accrued between November-3-2020 and Mar-31-2023. We found that 92 · 3% of patients received the primer vaccine, 70 · 8% received one monovalent booster, but only 30 · 1% received a bivalent booster. Booster uptake was lower under age 50, and among African American or Hispanic patients. Nearly all patients seroconverted after 2+ booster vaccinations (>99%) and improved cellular responses, demonstrating that repeated boosters could overcome poor response to vaccination. Receipt of booster vaccinations was associated with a lower risk of all-cause mortality (HR = 0 · 61, p = 0 · 024). Booster uptake in high-risk cancer patients remains low and strategies to encourage booster uptake are needed.

2024-08-01·British Journal of Haematology

Time to optimize vaccination strategies in blood cancer patients

Article

作者: Heslop, Helen E ; Muhsen, Ibrahim N

Immune response to vaccinations is dampened in patients with indolent lymphomas due to disease and treatment‐related factors. The study by Lim et al. demonstrated impaired humoral response but intact cellular response to the SARS‐CoV2 vaccine in patients with follicular lymphoma receiving front‐line therapy. The results highlight the importance of several factors in predicting immune response to vaccination and provide estimates of immune response for different clinical scenarios and treatment points.Commentary on: Lim et al. Immunogenicity of COVID‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy. Br J Haematol 2024;205:440‐451.

100 项与 CircRNA based SARS-CoV2 vaccines (Therorna Inc) 相关的药物交易

登录后查看更多信息